Check out your Company Bowl for anonymous work chats.
That’s a wrap for #AUA2025! From insightful demos to engaging conversations with leading experts, we’re thrilled with the impact QP-Prostate® CAD is making. Missed a chance to connect with Nathan Clark, Joshua Moss, Jason Santos, David Bazaga, or Ángel Alberich-Bayarri Bayarri about our AI-powered prostate cancer solution? Explore QP-Prostate® CAD 👉 https://bit.ly/44fUEIL 📅 Book a demo: https://bit.ly/3GaahY5 #AIinHealth #Urology #CancerScreening #MedicalInnovation
Heading to American Urological Association 2025? Let’s talk about prostate cancer and AI. Get to know QP-Prostate® CAD, our newly FDA-cleared tool available across the U.S. that streamlines fusion biopsies and focal therapy procedures through the power of AI to help uncover aggressive prostate cancer cases that may otherwise go undetected. 📍 Meet us at booth 2455 in Las Vegas 📅 Book a demo: https://bit.ly/3GaahY5 #AUA2025 #Urology #ProstateCancer #AIinHealth #MedicalInnovation
Medical imaging has come a long way, but traditional visual interpretation captures only a fraction of the available information. Enter radiomics - a valuable technology that extracts quantitative data from medical images to improve diagnosis, treatment planning, and research. Scroll right to see how it works and what role QP-Insights plays in all this. To understand it in more detail, explore the whole infographic on our website: https://bit.ly/3OrTBwX #Radiomics #MedicalImaging #PersonalizedMedicine #AIInHealthcare #HealthTech
#WorldLiverDay is the perfect occasion to highlight advances in liver health and how they contribute to a better future. Today we share a study involving our team: the MR-MASH score, a noninvasive tool that accurately identifies metabolic dysfunction-associated steatohepatitis (MASH) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) using MRI and waist circumference. ✅ Validated in 317 patients across Europe and the U.S. ✅ High diagnostic accuracy (AUC 0.88 discovery / 0.86 validation) ✅ Outperformed the FAST score (p < 0.001) ✅ Enables a two-step screening strategy with >80% PPV QP-Liver-derived imaging biomarkers facilitate automatic calculation of the MR-MASH score. This could transform how we diagnose and treat liver disease—faster, safer, and on a larger scale. https://bit.ly/42owKrO #LiverHealth #MedicalImaging #ClinicalResearch
🗞️ Make sure to read this article from Campus Sanofi, a Spanish-speaking educational platform for healthcare professionals, where they feature Quibim to explain from the inside how it is now possible for clinicians to diagnose earlier, monitor in real time and personalize treatments with the power of AI. ”𝘈𝘐 𝘰𝘷𝘦𝘳𝘤𝘰𝘮𝘦𝘴 𝘵𝘩𝘦 𝘭𝘪𝘮𝘪𝘵𝘢𝘵𝘪𝘰𝘯𝘴 𝘰𝘧 𝘵𝘳𝘢𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘳𝘢𝘥𝘪𝘰𝘮𝘪𝘤𝘴, 𝘰𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘮𝘰𝘳𝘦 𝘢𝘤𝘤𝘶𝘳𝘢𝘵𝘦 𝘱𝘳𝘰𝘨𝘯𝘰𝘴𝘦𝘴 𝘢𝘯𝘥 𝘪𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺 𝘪𝘯 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺".
The current standard for assessing tumor response in clinical trials - RECIST, performed by human readers - can be challenged by investigator bias, subjectivity in lesion selection and measurement variability. To address this, Quibim has partnered with Friends of Cancer Research on its artificial intelligence-based measurement of response evaluation criteria in solid tumors (ai.RECIST) project. The ai.RECIST project evaluates AI-based tumor measurement tools to: ✔️ Provide consistent and accurate tumor measurements ✔️ Align with expert RECIST readouts ✔️ Reduce variability and streamline trials Check Quibim's AI-supported RECIST tool, embedded in QP-Insights: https://bit.ly/3ELhH3p #aiRECIST #AIinResearch
The PROVIDENCE study, sponsored by Johnson & Johnson, S.A. in collaboration with Quibim, leverages artificial intelligence to predict metastatic relapse in patients with intermediate- to high-risk localized #ProstateCancer. 📊 Clinical data and diagnostic imaging are analyzed using the QP-Insights® platform to support non-invasive, real-time risk stratification. Interim results (n=127) demonstrate promising predictive performance for biochemical recurrence (AUC: 0.79), with surgery, PSA levels, and ISUP grade identified as key clinical predictors. Final results, currently in progress, will incorporate quantitative imaging biomarkers to further advance personalized treatment strategies. Read the full study here: https://bit.ly/42qjK4X #AIinHealthcare #MedicalImaging #Oncology #PrecisionMedicine
Our CEO and Co-Founder Dr. Ángel Alberich-Bayarri will join the stage at the European Conference on Interventional Oncology (ECIO) in Rotterdam to discuss: 𝘌𝘵𝘩𝘪𝘤𝘢𝘭, 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘢𝘯𝘥 𝘊𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘷𝘦 𝘜𝘴𝘦𝘴 𝘰𝘧 𝘈𝘐 𝘪𝘯 𝘐𝘯𝘵𝘦𝘳𝘷𝘦𝘯𝘵𝘪𝘰𝘯𝘢𝘭 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺. 🗓️ April 13, 2025 🕥 10:30–12:00 CET 📍 Auditorium 2, Rotterdam Ahoy Convention Centre - Rotterdam, The Netherlands 🎤 Moderators: Fernando Gómez Muñoz & Bernhard Meyer Join us for a critical conversation on how AI can be implemented responsibly to improve patient care. #InterventionalOncology #AIinHealthcare #EthicalAI #ECIO2025
This morning, we participated in the first edition of 𝘔𝘪𝘤𝘳𝘰𝘴𝘰𝘧𝘵 𝘏𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦 𝘋𝘢𝘺 in Madrid, an initiative organized by SEDISA (The Spanish Society of Healthcare Managers) in collaboration with Microsoft. The event aims to modernize the Spanish healthcare system through AI-powered technological solutions. Representing Quibim, our Chief Operations Officer Alberto Valiente Montoro, and Director of Business Development - EMEA, LATAM & APAC Javier Pizcueta Pastor, participated in the panel on the medical diagnosis and early detection of high-impact diseases. They shared how we apply artificial intelligence to transform the way these conditions are identified and managed. 👏 A big thank you for creating this space for innovation and fostering stronger collaboration between healthcare and technology. #DigitalHealth #ArtificialIntelligence #HealthcareInnovation
📢 Our CEO & Co-Founder Ángel Alberich-Bayarri participated in a Campus Sanofi Unboxing episode to share his vision on how AI is already helping radiologists detect diseases more accurately. Spanish-speaking healthcare professionals are sure to be interested! 👇
